VHH-based chimeric antigen receptor T cells against CD70 to eliminate primary and rechallenge renal cell carcinoma tumors in preclinical study.

被引：0
作者：
Jiang, Pengfei [1 ]
Xiong, Qinghui [1 ]
Wang, Haiying [1 ]
Deng, Tian [1 ]
机构：
[1] HRAIN Biotechnol, Shanghai, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e14540
引用
收藏
页数：1
相关论文
共 50 条
  • [41] The efficacy and applicability of chimeric antigen receptor (CAR) T cell-based regimens for primary bone tumors: A comprehensive review of current evidence
    Barzegari, Atefeh
    Salemi, Fateme
    Kamyab, Amirhossein
    Aratikatla, Adarsh
    Nejati, Negar
    Valizade, Mojgan
    Eltouny, Ehab
    Ebrahimi, Alireza
    JOURNAL OF BONE ONCOLOGY, 2024, 48
  • [42] Infusion of chimeric antigen receptor T cells against dual targets of CD19 and B-cell maturation antigen for the treatment of refractory multiple myeloma
    Tang, Fang
    Lu, Yin
    Ge, Yongqin
    Shang, Jingjing
    Zhu, Xiaming
    JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2020, 48 (01)
  • [43] Enhanced radiation-induced immunogenic cell death activates chimeric antigen receptor T cells by targeting CD39 against glioblastoma
    Sun, Ting
    Li, Yanyan
    Yang, Ying
    Liu, Bin
    Cao, Yufei
    Yang, Wei
    CELL DEATH & DISEASE, 2022, 13 (10)
  • [44] Enhanced radiation-induced immunogenic cell death activates chimeric antigen receptor T cells by targeting CD39 against glioblastoma
    Ting Sun
    Yanyan Li
    Ying Yang
    Bin Liu
    Yufei Cao
    Wei Yang
    Cell Death & Disease, 13
  • [45] Preclinical characterization of switchable allogeneic chimeric antigen receptor T cells to support first in human clinical study in CD123-positive hematologic and lymphatic malignancies
    Ehninger, Armin
    Spehr, Johannes
    Loff, Simon
    Langer, Anika
    Riewaldt, Julia
    Reinhardt, Julia
    Meyer, Jan-Erik
    Dietrich, Josephine
    Jurado, Gabriel
    Lescarbeau, Reynald
    Cartellieri, Marc
    CANCER RESEARCH, 2023, 83 (07)
  • [46] A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR (vol 119, pg 5697, 2012)
    Torikai, H.
    Reik, A.
    Liu, P-Q
    BLOOD, 2015, 126 (22) : 2527 - 2527
  • [47] Anti-CD37 chimeric antigen receptor T cells are active against B-and T-cell lymphomas (vol 132, pg 1495, 2018)
    Scarfo, I
    Ormhoj, M.
    Frigault, M. J.
    BLOOD, 2018, 132 (23) : 2527 - 2527
  • [48] Anti-proliferative effects of T cells expressing a ligand-based chimeric antigen receptor against CD116 on CD34+ cells of juvenile myelomonocytic leukemia
    Nakazawa, Yozo
    Matsuda, Kazuyuki
    Kurata, Takashi
    Sueki, Akane
    Tanaka, Miyuki
    Sakashita, Kazuo
    Imai, Chihaya
    Wilson, Matthew H.
    Koike, Kenichi
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2016, 9
  • [49] Anti-proliferative effects of T cells expressing a ligand-based chimeric antigen receptor against CD116 on CD34+ cells of juvenile myelomonocytic leukemia
    Yozo Nakazawa
    Kazuyuki Matsuda
    Takashi Kurata
    Akane Sueki
    Miyuki Tanaka
    Kazuo Sakashita
    Chihaya Imai
    Matthew H. Wilson
    Kenichi Koike
    Journal of Hematology & Oncology, 9
  • [50] Fratricide-Resistant Anti-CD2 Chimeric Antigen Receptor T-Cells with Endogenous CD2 Knockout Are Highly Effective Against T-Cell Neoplasms
    Angelos, Mathew G.
    Patel, Ruchi P.
    Chiang, Hao
    Xie, Wei
    Pajarillo, Raymone
    Shaw, Carolyn E.
    Singh, Ekta
    Xu, Jason
    Posey, Avery D.
    Rook, Alain
    Rotolo, Antonia
    Pillai, Vinodh
    Pileri, Stefano A.
    Teachey, David T.
    Ruella, Marco
    BLOOD, 2023, 142
12345